Jiangsu Vcare Secures Over CNY 450 Million in Series C Funding
Published Time:
2024-01-02 17:34
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C financing round, raising over CNY 450 million. The investment consortium included China Life Private Equity Investment, DYEE Capital, Hongyao Technology Capital, existing investor Nanjing Innovation Capital Group, and Hangzhou Huadian Investment. The participation of new investors alongside continued support from existing shareholders demonstrates strong market confidence in Jiangsu Vcare’s growth trajectory. Proceeds will accelerate the advancement of its innovative drug pipeline and strengthen its integrated CRO/CDMO services across the pharmaceutical value chain.
The successful Series C closing amid challenging market conditions underscores Jiangsu Vcare’s robust development potential and competitive advantages. Since its inception, the company has pursued a dual-core strategy: proprietary innovative drug development and comprehensive CRO/CDMO services. This approach prioritizes independent innovation and client-centric solutions. Currently, both business pillars demonstrate rapid growth: Multiple clinical-stage drug candidates approaching key milestones; Sustained expansion of CRO/CDMO business; Established a fortified competitive "moat" through differentiated products, technologies, and services; With robust investor backing, Jiangsu Vcare is positioned to achieve high-quality development.
Dr. Gong Yanchun, Co-founder and CEO, stated: "We view financing not merely as capital-raising, but as forging a shared-destiny partnership with values-aligned, committed, and professional collaborators to achieve meaningful impact. Securing this round during the industry-wide 'winter' reflects capital markets’ recognition of Vcare’s team and vision. At this new developmental stage, we remain steadfastly focused on our dual-core strategy. Through differentiated approaches and by seizing policy and market opportunities, we will advance courageously and steadily in innovative drug R&D and pharmaceutical services. While accelerating our own high-quality growth, we are committed to contributing to the pharmaceutical industry’s sustainable advancement."
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn